![]() |
|
|
Forward to a colleague |
||
Access Full Stories Bristol-Myers Squibb (BMS) has revealed plans to close another site in Puerto Rico in its latest cost-cutting move... Read Pharmaceutical outsourcing: people on the move Cobra Biomanufacturing, Draxis, BioReliance, Quintiles and Premier Research Group have all had people on the move in the world of pharmaceutical outsourcing... Read Icon forays further into Eastern Europe Dublin-based contract research organisation (CRO) Icon Clinical Research has forayed further into Eastern Europe with the opening of three new offices there... Read Bridge to bolster China biz Bridge Laboratories will bolster its China operations again after scoring itself a further $18m worth of venture capital funding... Read FDA considering establishing Indian presence The US Food and Drug Administration (FDA) is considering establishing a presence in India, amidst the country's growing ties with the US pharma industry... Read |
||||||||||||||
All News Headlines for: January | December | November |
||||||||||||||
![]() Introducing Catalent Pharma Solutions Catalent Pharma Solutions is the leading provider of advanced technologies as well as development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer health companies in nearly 100 countries... Click Here | ||||||||||||||
|
Related Industry News Ventana gives in to Roche merger following increased offer After seven months of offers, refusals and heated exchanges, it seems an increased offer from Roche has finally persuaded the powers that be at Ventana to sell up... Read Roche ramps up biotech Roche has announced major investments at three of its European sites, continuing its drive to strengthen its position in the biopharmaceutical market... Read EC launches major pharma industry probe The European Commission has launched an investigation into the entire European pharmaceutical sector, with surprise raids on a number of manufacturers in a bid to unearth any evidence of foul-play hampering the... Read Novo drops inhaled insulin plans in post-Exubera fallout Mere months after Pfizer's high profile exit from the inhaled insulin market in the wake of Exubera's much publicised market failure, Novo Nordisk announced late last night that it, too, has decided to halt development... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2008 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||